Skip to main content
. 2022 Aug 8;12(11):4204–4223. doi: 10.1016/j.apsb.2022.07.023

Figure 2.

Figure 2

SRF downregulated the expression of PD-L1 in cancer cells through AMPK and STAT1 pathways regulation. (A–F) Expression of the PD-L1 and p-AMPK protein in MB49 and B16F10 tumor cells revealed by Western blot assay and the corresponding protein quantification by ImageJ after the treatment of different concentrations of SRF for 24 h (n = 3). (G, H) PD-L1 protein expression in MB49 cells and protein quantification after 20 ng/mL IFN-γ treatment with or without 8 μmol/L SRF for 24 h (n = 3). (I–K) The PD-L1 expression in MB49 cells evaluated by immunofluorescent staining and flow cytometry assay after 8 μmol/L SRF treatment in the presence or absence of AMPK inhibitor (20 μmol/L Compound C) (n = 3), scale bar = 20 μm. (L, M) Detection of the Tyr701 phosphorylation of STAT1 by Western blot assay after the addition of IFN-γ in the absence or presence of SRF treatment (n = 3). (N) Schematic diagram presenting the mechanism of SRF-mediated PD-L1 lower expression. Data are demonstrated as mean ± SD. Statistical analysis was performed via the two-tail Student’s t-test. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001.